Days after approving a $150 million class action settlement between direct purchasers of nasal spray Flonase and manufacturer GlaxoSmithKline, a federal judge has approved a $35 million settlement between GSK and the indirect purchasers of the drug.
In approving the $35 million settlement in In re Flonase Antitrust Litigation, U.S. District Senior Judge Anita B. Brody of the Eastern District of Pennsylvania also awarded nearly $11.7 million in attorney fees and $1.85 million in expenses to the plaintiffs' class counsel. Fifteen firms worked on the case with lead counsel Miller Law and Pomerantz Grossman Hufford Dahlstrom & Gross logging the majority of the 37,762 hours worked over the nearly five years of litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
